TG Therapeutics, Inc.;Rhizen Pharmaceuticals SA;Laboratoire Francais Du Fractionnement Et Des Biotechnologies
发明人:
Michael S. Weiss,Hari P. Miskin,Peter Sportelli
申请号：
US16331407
公开号：
US20190247399A1
申请日:
2017.09.08
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure provides methods and kits for treating or slowing the progression of a hematological malignancy, by administering to a subject in need thereof a therapeutically effective amount of: (i) at least one inhibitor of PI3 kinase (PI3K)-delta (e.g., TGR-1202)； (ii) at least one anti-CD20 antibody (e.g., ublituximab)； and (iii) at least one anti-PD-1 antibody (e.g., pembrolizumab) or anti-PD-Ll antibody (e.g., atezolizumab). Treatment regimens are also provided.
